2 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
Follow Neoplasms, Second Primary: new trials by email Literature Review of Neoplasms, Second Primary trials Research Report on Neoplasms, Second Primary
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation Panitumumab, Irinotecan, Folinic acid - Treatment Related Cancer | Phase 2 | Terminated | Ludwig-Maximilians - University of Munich | 3 | 2019-07-24 | 2026-08-27 |
| Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2) temozolomide - Breast Neoplasm, Brain Neoplasm | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 6 | 2008-10-02 | 2017-06-14 |
Brain Neoplasms (1) · Breast Neoplasms (1) · Colorectal Neoplasms (1)
Neoplasms (2) · Neoplasms by Site (2) · Brain Diseases (1) · Breast Diseases (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Intestinal Diseases (1) · Intestinal Neoplasms (1) · Nervous System Diseases (1) · Nervous System Neoplasms (1)
Fluorouracil (1) · Irinotecan (1) · Leucovorin (1) · Panitumumab (1) · Temozolomide (1)
Ludwig-Maximilians - University of Munich (1) · Merck Sharp & Dohme LLC (1)
Germany (1)